ArticleNeoplasia (New York, N.Y.)2026
An intron retention-derived secreted Endoglin Isoform as a circulating biomarker in pancreatic ductal adenocarcinoma.
Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with few effective strategies for early detection or prognostic assessment. Endoglin (CD105) is an endothelial receptor best known for its roles in vascular development and tumor angiogenesis, and its only recognized circulating form arises through proteolytic shedding of the full-length receptor. Here, we report a pancreatic tumor-derived secreted endoglin isoform that is molecularly distinct from all known endoglin variants, enabling the development of an isoform-specific antibody for selective detection. Through integrated transcriptomic, biochemical, and translational analyses, we identified a truncated endoglin isoform generated by intron retention that contains a unique C-terminal peptide absent from canonical endoglin. This isoform was detected in human PDAC cell lines, orthotopic xenografts, primary patient tumors, patient sera, and the KPC genetically engineered mouse model, demonstrating conservation across clinically relevant systems. Tissue microarray analysis revealed that the isoform is prevalent in PDAC and represents a major subset of endoglin-positive tumors, while immunoprecipitation and a newly developed sandwich ELISA confirmed its presence in patient circulation, supporting its potential as a blood-based biomarker. Together, these findings identify a previously unrecognized, tumor-derived secreted endoglin isoform and highlight intron retention as source of circulating protein biomarkers in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.